Global Axial Spondyloarthritis Epidemiology and Patient Flow Analysis - 2017
Fore Pharma announced the results of its Axial Spondyloarthritis patients study in a new report ‘Global Axial Spondyloarthritis Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Axial Spondyloarthritis epidemiology, Axial Spondyloarthritis diagnosed patients, and Axial Spondyloarthritis treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Axial Spondyloarthritis derived from epidemiological analysis, percentage of patients diagnosed with Axial Spondyloarthritis, and percentage of patients treated with a therapy.
The study helps executives estimate Axial Spondyloarthritis market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Axial Spondyloarthritis prevalence, Axial Spondyloarthritis diagnosis rate, and Axial Spondyloarthritis treatment rate for the period 2016 - 2025. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.